Sugi Predict

Sugi Predict / Compounds / SCHEMBL1127697

SCHEMBL1127697

SCHEMBL1127697

CN1CCN(CC(=O)OCc2ccccc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.58
▸ PPARA Q07869 1/20 0.58
▸ ALDH1A1 P00352 4/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MAPK1 P28482 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MC4R P32245 1/20 0.51
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ ITGB3 P05106 1/20 0.49
▸ ITGA2B P08514 1/20 0.49
▸ HTR1A P08908 1/20 0.49
▸ ADRA2A P08913 1/20 0.49
▸ ADRA2B P18089 1/20 0.49
▸ ADRA2C P18825 1/20 0.49
▸ DRD1 P21728 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24251635 0.92 ALDH1A1 (0.59) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL15985781 0.88 ALDH1A1 (0.53) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL14446963 0.88 ALDH1A1 (0.52) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL17921387 0.88 ALDH1A1 (0.53) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL15776693 0.88 ALDH1A1 (0.55) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL25419509 0.88 ALDH1A1 (0.55) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL5548988 0.88 ALDH1A1 (0.55) PPARGPPARAALDH1A1RAB9ASMN1; SMN2
SCHEMBL21421643 0.87 ALDH1A1 (0.52) PPARGPPARAALDH1A1SMN1; SMN2MAPK1
SCHEMBL25001507 0.86 ALDH1A1 (0.64) ALDH1A1RAB9ASMN1; SMN2MAPK1L3MBTL1
SCHEMBL3569051 0.86 ALDH1A1 (0.68) ALDH1A1RAB9ASMN1; SMN2MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104622809-B The drug of modification for elaioplast nanometer particle 英属哥伦比亚大学 2019-04-19 — — CN disclosed
EP-3415151-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES The University of British Columbia (CA) 2018-12-19 — — EP disclosed
EP-2282724-B1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES UNIV BRITISH COLUMBIA (CA) 2018-09-05 — — EP disclosed
US-20180221279-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES UNIV BRITISH COLUMBIA (CA) 2018-08-09 — — US disclosed
US-20180221279-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES UNIV BRITISH COLUMBIA (CA) 2018-08-09 — — US disclosed
US-9968554-B2 Modified drugs for use in liposomal nanoparticles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2018-05-15 — — US disclosed
US-9968554-B2 Modified drugs for use in liposomal nanoparticles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2018-05-15 — — US disclosed
CN-102105135-B Modified drugs for liposomal nanoparticles 英属哥伦比亚大学 2016-08-24 — — CN disclosed
CN-104622809-A Modified drugs for use in liposomal nanoparticles UNIV BRITISH COLUMBIA 2015-05-20 — — CN disclosed
US-20140356417-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2014-12-04 — — US disclosed
CN-102105135-A Modified drugs for liposomal nanoparticles UNIV BRITISH COLUMBIA 2011-06-22 — — CN disclosed
EP-2282724-A2 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES The University Of British Columbia (CA) 2011-02-16 — — EP disclosed
WO-2009141738-A2 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2009-11-26 — — WO disclosed
EP-1238974-B1 HETEROCYCLE DERIVATIVES AND DRUGS NIPPON SHINYAKU CO LTD (JP) 2007-05-23 — — EP disclosed
EP-1501800-A1 BOMBESIN ANTAGONISTS Warner-Lambert Company LLC (US) 2005-02-02 — — EP disclosed
US-6787546-B2 POTENT ANTICANCER ACTIVITY; WATER SOLUBLE; INJECTION 4-(2-(2-(N-(4-METHOXYBENZENESULFONYL)-N -PIPERIDINOACETYLAMINO)PHENYL)ETHENYL)PYRIDINE 1-OXIDE HYDROCHLORIDE NIPPON SHINYAKU CO., LTD. (JP) 2004-09-07 — — US disclosed
US-20040063643-A1 Bombesin antagonists PFIZER INC. 2004-04-01 — — US disclosed
WO-2003092670-A1 BOMBESIN ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2003-11-13 — — WO disclosed
US-20030022884-A1 Heterocycle derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2003-01-30 — — US disclosed
EP-1238974-A1 HETEROCYCLE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2002-09-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063643-A1 Bombesin antagonists BRS3, NPSR1, GNRHR PPARG 3817/4885PPARA 3913/4885ALDH1A1 3777/4885
US-20180221279-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES ABCB11, SLC47A1, ABCB1 PPARG 3807/4885PPARA 2964/4885ALDH1A1 1273/4885
US-20140356417-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES ABCB11, SLC47A1, ABCB1 PPARG 3807/4885PPARA 2964/4885ALDH1A1 1273/4885
US-20030022884-A1 Heterocycle derivatives and drugs ABCC5, CYP3A5, CYP2D6 PPARG 2246/4885PPARA 1910/4885ALDH1A1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.